Suggested Remit: To appraise the clinical and cost effectiveness of rucaparib within its marketing authorisation for maintenance treatment of recurrent epithelial ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy.
 
Status In progress
Process STA 2018
ID number 1485

Provisional Schedule

Committee meeting: 1 16 July 2019
Expected publication 02 October 2019

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Consultees

Companies sponsors Clove Oncology
Others Department of Health Social Care
  NHS England
  Welsh Government
Patient carer groups Ovarian Cancer Action
  Target Ovarian Action
Professional groups Association of Cancer Physicians
  British Gynaecological Cancer Society
  British Society for Radiology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies AstraZeneca
Evidence review group BMJ Technology Assessment Group
  National Institute for Health Research Health Technology Assessment Programme (NETSCC)
General commentators Department of Health , Social Services and Public Society - Northern Ireland
  Healthcare of improvement Scotland
  Welsh Health Specialised Services Committee
  Scottish Medicines Consortium

Timeline

Key events during the development of the guidance:

Date Update
16 November 2018 Invitation to participate
18 September 2018 - 16 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
27 June 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance